Thanks to the improving new drug approval system and the wide application of new technology in China,the development of traditional Chinese medicine (TCM) meets the golden opportunity at the best conditions.In the further research of new drugs,effective data mining of ancient literatures and clinical medication experience need paying more attention supported by research data of clinical efficacy of new Chinese drugs,as it is generally recognized,for the establishment of the approval system of syndrome types.In addition,we should prudently value the safety issues on TCM and improve the classification and registration of new Chinese drugs and drug approval in the future.Therefore,the research and development of modern drugs,evaluation standard and review experience of new Chinese drugs in the recent three decades need integrating for the establishment of the improvement of the technology system of drug review and registration in conformity with the characteristics of TCM of great significance in the clinical service and industrial development of TCM.

To investigate the possible nephrotoxicity of Compound Decoction of Caulis Aristolochiae Manshuriensis (CDCAM). Body weight, blood pressure, hemoglobin and renal functions, especially of urinary low-molecular weight protein in patients were observed before and after a short-term ( 0.05 ).[Conclusion]The nephrotoxicity of Caulis Aristolochiae Manshuriensis may be associated with the long-term over-dose administration and without TCM syndrome differentiation.

Evidence-based medicine advocates that decision making should be based on the adequate evidence. High quality systematic review is an important source of information for clinicians, patients, governments and other decision makers in decision making. If reviewers couldn't master the correct method of systematic review or meta-analysis was misused, the inaccurate, biased or misleading outcomes would be produced. So understanding of the methods of evaluating the quality of systematic review and meta-analysis is helpful to make good use of the review's information.

Objective: To explore the therapeutic mechanism of Qingnao Yizhi Formula (QYF) for vascular dementia and multi - infarct dermentia. Methods: In- vitro rabbit neuron culture was utilized to investigate the effect of QYF on glutamic - acid - induced neuron injury. Results: QYF could increase the survival rate of iniured neuron(P

Objective To develop a method for the determination of four saponins of panax notoginseng in Compound Dan-shen Prescription (CDP) by HPLC. Methods The conditions for the experiment were: determination of notoginsenoside R1, ginsenoside Rg1 and ginsenoside Re with acetonitrile - 0. 05 % phosphoric acid (19 : 81) as mobile phase and the detection wave at 203nm, determination of ginsenoside Rb1 with acetonitrile - water (33 : 67) as mobile phase and the detection wave at 203nm. Results A good linearity for notoginsenoside R1 was in the range of 0. 24 ~ 3. 6?g ( r = 0. 9997), 1. 2 ~ 18?g (r = 0. 9994) for ginsenoside Rg1, 0. 08 ~ 1. 2?g(r = 0. 9997) for ginsenoside Re and 0. 25-3. 72?g (r = 0. 9998) for ginsenoside Rb1. The stability of the four saponins is well kept at 4℃ for four months. Conclusion This method is simple, rapid, accurate and with good reproducibility and can be used for the quality control of CDP.

Objective To observe the effect of Huangqi Danshen Drop Pill(HDDP) on pituitary (Pit) induced acute myocardium ischemia. Methods Acute myocardium ischemia rat model was established by sublingual venous injection of Pit(0. 35U/kg). The changes of the T wave ( II channel ECG) and serum contents of lactate dehydrogenase (LDH), CK, superoxide dismutase (SOD) and malondialdehyde (MDA) were observed in various times after Pit injection. Results HDDP could significantly lower the height of T waves, increase SOD activity and decrease MDA content. Conclusion HDDP can improve acute myocardium ischemia induced by Pit.

Authors defined the concept of drug packaging wastes,and analyzed the current administration of such waste recycling in China.With reference to experiences of other countries and Taiwan,the paper proposed to refine the legal framework for recycling drug packaging waste in China,by categorizing to set up the categorized recycling mechanism,and by refining the process to build the reverse logistics recycling system.